Internal Medicine Alert – April 15, 2018
April 15, 2018
View Archives Issues
-
Elderly May Not Benefit From Statins for Primary Prevention
In an examination of the data from the much-publicized Systolic Blood Pressure Intervention Trial (SPRINT), the author found no benefit of statin therapy for primary prevention of cardiovascular events or all-cause mortality.
-
Stroke Risk in Atrial Fibrillation: A Moving Target?
An investigation of patients in a national database with atrial fibrillation, no comorbidities, and not on aspirin or anticoagulants showed that the clinical features that make up the CHA2DS2-VASc score change over time and can increase a patient’s risk for stroke, which could affect therapy decisions. Thus, the CHA2DS2-VASc score should be reassessed periodically and appropriate therapeutic actions taken promptly.
-
After Myocardial Infarction, Increased Risk for Ischemic Stroke Persists for 12 Weeks
This study establishes that the elevated short-term risk of stroke extends beyond 30 days and remains elevated for up to 12 weeks following acute myocardial infarction.
-
Ibalizumab-uiyk Injection (Trogarzo)
Ibalizumab-uiyk, in combination with other antiretrovirals, is indicated for the treatment of HIV-1 in heavily treatment-experienced adults with multidrug-resistant HIV infections failing their current regimens.
-
Clinical Briefs
In this section: comparing GLP-1 agonists; weighing two treatments for extended venous thromboembolism; and considering fracture risks possibly associated with inhaled corticosteroids.
-
What Form of AV Block?
The long lead II rhythm strip shown in the figure was obtained from a hemodynamically stable patient. The rhythm was diagnosed as showing second-degree AV block, Mobitz Type II. Do you agree with that assessment?